Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518.
about
Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemia.Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinicFLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia.Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamicsFluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemia.RNA interference for treating haematological malignancies.Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin.Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patternsHigh-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia.Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors.Potential role of sorafenib in the treatment of acute myeloid leukemia.FMS-like tyrosine kinase 3 inhibitors: a patent review.The clinical development of FLT3 inhibitors in acute myeloid leukemia.New therapeutic approaches to acute myeloid leukemia.FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance.FLT3 inhibitors in AML: are we there yet?FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors.BH3-only protein Bim more critical than Puma in tyrosine kinase inhibitor-induced apoptosis of human leukemic cells and transduced hematopoietic progenitors carrying oncogenic FLT3.Inhibition of apoptosome formation by suppression of Hsp90beta phosphorylation in tyrosine kinase-induced leukemias.Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways.FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248).NDEL1-PDGFRB fusion gene in a myeloid malignancy with eosinophilia associated with resistance to tyrosine kinase inhibitors.Tandutinib inhibits FMS receptor signalling, and macrophage and osteoclast formation in vitro.Receptor kinase profiles identify a rationale for multitarget kinase inhibition in immature T-ALL.Tyrosine kinase inhibitor insensitivity of non-cycling CD34+ human acute myeloid leukaemia cells with FMS-like tyrosine kinase 3 mutations.Rapid detection of FLT3 exon 20 tyrosine kinase domain mutations in patients with acute myeloid leukemia by high-resolution melting analysis.Resistance to FLT3 inhibitors in acute myeloid leukemia: Molecular mechanisms and resensitizing strategies
P2860
Q33767026-AA9105BF-ECA2-4998-BE22-C907E14FD62FQ34011740-85D737F9-1204-42BD-912F-E9050C55F8F9Q34817365-BBB9FA03-B057-4A6D-9209-1577964D316BQ34993145-740E0B94-83C2-42CA-AD8E-C4D40D820ED7Q35848830-354E9020-2604-4F61-BD26-D7331C3BC025Q36318153-C5CA885E-46EB-44D8-AAF1-089CAF84A8B4Q36327055-ACCAB38C-FC4D-41BF-BA47-9D0538D9E1AEQ36447942-2397809F-59F6-4EE6-8CB7-5EF6DBB78FC9Q36469916-BCAF7030-7AED-4314-9CEE-251B517D91E3Q36591388-B150BAF8-362F-4ED4-A6D9-EC1B812FCC91Q37294768-5CA103FC-C650-4BD4-A55D-96731D787271Q37340403-B3376945-591F-4104-918E-3EB01AF9F7CAQ37842585-118C59D9-D146-4092-BE15-F7586D6AC317Q37927089-A5E640B5-5115-4653-A340-FF07BC92A030Q38090673-9D4E5029-8786-4A88-9D89-7A3702FA2738Q38101284-86640582-506B-4F88-A692-20C346696803Q38200564-9AD8E928-25D1-4F3A-B38A-00AB26FBFFCDQ38721796-A74737F0-93F8-424D-8F13-8E41E61DE7DEQ39907753-DBDC7CDF-FFC0-4E09-9A61-49A5CF842EF1Q39966770-C0B8F073-7D8D-4FA2-8836-BF93BB2B8D00Q40218888-20FB7E0B-9B06-464E-AF8F-D771636B407CQ40228769-41D386F6-CF99-4B48-B8EE-85CA4DF7A9D9Q40401088-51D5295E-F985-4F12-A238-A1BB0EC52EB4Q46815326-FD9E6B73-137E-4E6D-AC96-CD04D595E1D0Q47429067-98D5791A-2CE4-48DC-B9B4-071D2FDF261CQ53239474-AF4CC4C8-5696-4273-9B6F-59B1839B1BF6Q54546181-62F36054-2A95-467A-BEF1-EE698B44E702Q58739975-4E99D79C-471B-47B2-98A1-FE0CDD07BC47
P2860
Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Variable sensitivity of FLT3 a ...... osine kinase inhibitor MLN518.
@en
type
label
Variable sensitivity of FLT3 a ...... osine kinase inhibitor MLN518.
@en
prefLabel
Variable sensitivity of FLT3 a ...... osine kinase inhibitor MLN518.
@en
P2093
P1433
P1476
Variable sensitivity of FLT3 a ...... osine kinase inhibitor MLN518.
@en
P2093
D Gary Gilliland
David P Curley
Jennifer J Clark
Jin-Chen Yu
Nathalie A Lokker
Neill A Giese
P304
P356
10.1182/BLOOD-2003-12-4446
P407
P50
P577
2004-07-15T00:00:00Z